The Hypertension Clinic is a part of the Internal Medicine

Similar documents
JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

THE IMPACT OF CCB AND RAS INHIBITOR COMBINATION THERAPY TO PREVENT CKD INCIDENCE IN HYPERTENSION AND ADVANCED ATHEROSCLEROSIS

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

DEPARTMENT OF GENERAL MEDICINE WELCOMES

Update on Current Trends in Hypertension Management

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

How clinically important are the results of the large trials in hypertension?

A fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension: Results of a noninvestigational

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017

What s In the New Hypertension Guidelines?

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines

Effective Date: TBD Version: 1.0 (Revised: 6/11/2014)

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

hypertension Head of prevention and control of CVD disease office Ministry of heath

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Jared Moore, MD, FACP

Reframe the Paradigm of Hypertension treatment Focus on Diabetes

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Diversity and HTN: Approaches to optimal BP control in AfricanAmericans

Director of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Long-Term Care Updates

International Journal of Advancements in Research & Technology, Volume 2, Issue 6, June-2013 ISSN

An Epidemiological Overview

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

Blood Pressure Lowering Efficacy of Perindopril/ Indapamide Fixed Dose Combination in Uncontrolled Hypertension

Egyptian Hypertension Guidelines

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

Hypertension mechanisms

Prevention of Heart Failure: What s New with Hypertension

By Prof. Khaled El-Rabat

New Antihypertensive Strategies to Improve Blood Pressure Control

Correlation of LV Longitudinal Strain by 2D Speckle Tracking with Cardiovascular risk in Elderly. (A pilot study of EGAT-Echo study.

Characteristics and Future Cardiovascular Risk of Patients With Not-At- Goal Hypertension in General Practice in France: The AVANT AGE Study

Combination Therapy for Hypertension

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension

The ESC Registry on Chronic Ischemic Coronary Disease

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Hypertension Management Focus on new RAAS blocker. Disclosure

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)

Managing hypertension: a question of STRATHE

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

Hypertension Update Background

Hypertension Guidelines 2017

Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14

Prevention of Cardiovascular Disease

Use of Antihypertensive Medications in Patients with type -2 Diabetes in Ajman, UAE

T. Suithichaiyakul Cardiomed Chula

Measure Up/Pressure Down Medical Group Success

Hypertension Update. Aaron J. Friedberg, MD

Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient

Antihypertensive Trial Design ALLHAT

Pattern of Use of Anti-Hypertensive Drugs In a North Indian Tertiary Care Hospital Renu, Hema Chhabra, Anita Gupta, Neetu Sharma

Cardiovascular Diseases in CKD

Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study

The CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES

The Effect of Isosorbide Dinitrate Intravenous Injection on the Hemodynamics and Arterial Stiffness of Patients with Isolated Systolic Hypertension

2014 HYPERTENSION GUIDELINES

Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension)

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES

Clinical cases with Coversyl 10 mg

An Epidemiological Overview

How Low Do We Go? Update on Hypertension

Treating Hypertension in Individuals with Diabetes

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

The Road to Renin System Optimization: Renin Inhibitor

Nurse-sensitive factors in hypertension management

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

TIP. Documentation and coding guide. Disease definitions* Prevalence and statistics associated with HTN**

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD

47 Hypertension in Elderly

Module 3.2. Management of hypertension at primary health care

First line treatment of primary hypertension

Hypertension and Cardiovascular Disease

Diabetes and Hypertension

Received: / Revised: / Accepted: / Published:

Approximately 73.6 million adults in the United States have

Cardiovascular Disease Risk Factors and Blood Pressure Control in Ambulatory Care Visits to Physician Offices in the U.S.

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Osama Sanad (MD) Prof. of Cardiology Benha University 2016

Hypertension Update 2009

Hypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Summary of recommendations

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

Hypertension (JNC-8)

The Evolution To Treatment Of Hypertension With Advanced Formulation

JMSCR Vol 06 Issue 05 Page May 2018

Hypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington

Disclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1

Layered Approaches to Studying Drug Responses

Transcription:

Original Article Hypertension Registry at the Bangkok Hospital Medical Center: The First 7 Months Experience OBJECTIVE: The Hypertension Registry at the Bangkok Hospital Medical Center was established in June 2012. It aimed to raise awareness of the availability of appropriate hypertension health services, to optimize the quality of care, and to systematically build a database of clinical outcomes. The purpose of this article is to highlight the main data collected from patients with hypertension who took part in the Hypertension Registry Programme. These findings will help improve services and will lead to better clinical outcomes in the future. Rungtanapirom S, MD email : surachai.ro@bgh.co.th Surachai Rungtanapirom, MD 1 Jitraporn Khankam, RN 1 Naphat Benjakhunprasit, RN 1 Atittaya Sitthiphattarakul, RN 1 Pornchai Tantivanon 2 Akarawat Kiatdum 2 1 Medicine Unit, Bangkok Hospital, Bangkok Hospital Group, Bangkok, Thailand. 2 Strategic information management service, Greenline Synergy Co.Ltd, Bangkok, Thailand. Keywords: hypertension registry, hight blood pressure, Bangkok Hospital, Thailand MATERIALS AND METHOD: A retrospective review was conducted of all the participants in the Hypertension Registry from June 2012 to December 2012. Descriptive data is presented as absolute numbers and percentages. RESULTS: A total of 647 patients with hypertension were registered, half of all registrants were overweight, 51.9 had dyslipidemia and 34.8 had diabetes. The most frequent investigations done to assess cardiovascular risk were electrocardiograms (EKG) 34.4; chest x-rays 27.9; Ankle Brachial Index (ABI) 19.5; and urine microalbumin (MAU) 18.1. In 3.9 of cases no antihypertensive medication was required and 53.5 of patients were prescribed a single item of medication. Angiotensin-receptor blockers (ARB) were the most frequently prescribed antihypertensive medication. Up to 90 of cases were well controlled and achieved a systolic blood pressure (SBP) < 140 mmhg. and diastolic blood pressure (DBP) < 90 mmhg. CONCLUSION: The Hypertension Registry at the Bangkok Hospital Medical Center provides multiple advantages in collecting relevant information to further optimize the quality of hypertensive services offered and to improve the quality of life of patients with hypertension. The Hypertension Clinic is a part of the Internal Medicine Outpatient department (OPD) at the Bangkok Hospital Medical Center. Hypertension patients account for 15 of all Internal Medicine OPD visits. It is now widely accepted that hypertension management is also a concern to other cardiovascular risk factors. Besides the process of measuring blood pressure and prescribing medications, better management can help prevent more cardiovascular vascular complications. 1-4 The primary goals of the Hypertension Registry are: 1) to create data as a tool for quality control (QC) to help improve the quality of future services and planning 2) to create awareness of other associated medical conditions that are risk factors beyond blood pressure levels in both patients and service providers to increase public awareness The Bangkok Medical Journal Vol. 5; February 2013 1

Rungtanapirom S, et al. 3) to make use of electronic medical records (EMR) to benefit both patients and service providers 4) to improve service efficiency and continuous education of clinical staff and physicians by periodically creating feedback data reports During the first seven months of the Hypertension Registry, 647 patients with hypertension enrolled in the programme. The objective of the study is to highlight the main data of patients who registered in the programme compared to a group enrolled in one physician s hypertension registry. Materials and Methods The Hypertension Registry was established in June 2012. Patients demographic and clinical information of is retrieved from two data sources: the electronic medical records (EMR) and collating information by hand. The process to create a registry entry is as follows: The staff 1) Coordinator Nurses (who also play a role as educators) open each case entry by inputting the initial information (a new case entry is partly picked up from ICD-10 diagnosis in the department and some cases are opened by physicians themselves or through physician assistants who inform the nurse coordinators). An icon is created in the EMR for each case and flagged as a hypertension registry member case. A review and data input for antihypertensive medications prescribed is inputted, plus information is audited to check the entries are correct. A summary is generated periodically (every 3-6 months) with assistance from Information Technology staff to create reports for the Hypertension Clinic and as a feedback information mechanism for the physicians involved. 2) Physician Assistants coordinate physicians and coordinators. 3) Physicians who attend the patient and act as team consultants. 4) Information Technology (IT) staff help the team from an early stage in the process and create appropriate software for the electronic medical records, create additional input questionnaires for specific data, and create programmes for the data summary system. The Process 1) The demographic information of each registrant is linked to the EMR once the patient is entered into the hypertension registry and a HT icon is created on each individual EMR to flag the patient as a member of the registry. The patient s past history and any associated illnesses are reviewed from the EMR and the patient record files and also available including interviewing the patient during an education session conducted by a nurse coordinator. 2) Laboratory investigations identify any organ damage i.e. EKG, echocardiography, chest x-ray, urine for microalbumin (MAU) and Ankle Brachial Index (ABI) by using a vascular screening machine VaSera (this machine measures both ABI x CAVI) which also measures a Cardio-Ankle Vascular Index (CAVI). 5-8 The results of each investigation are retrieved from the EMR and input into the registry by directly linking the information to the date the investigations were performed. At present, only the linked information can be accessed in bulk but the results from various measurements still need to be input manually. 3) Medication use was reviewed from the EMR and the medical records file. Antihypertensive medication was classified into 9 groups; 1) Diuretics, 2) Dihydropyridine calcium channel blockers (DHP CCB), 3) Non dihydropyridine (non DHP CCB), 4) Angiotensin-converting enzyme inhibitors (ACEI), 5) Angiotensin II receptor blockers (ARB), 6) Direct renin inhibitors (DRI), 7) Alpha blockers, 8) Beta blockers, and 9) Others. The combination antihypertensive tablet was counted as 2 or 3 isolated medications that are the components of the pill prescribed at the same time. The medication is entered by trade name and is automatically allocated to the group they belong to in accordance with the preset lists of the antihypertensive medication database. 4) At each visit the registrant s height (cm), and body weight (kg) is reviewed and this data is added to the individual s database by the physician assistants. Blood pressure values (both systolic and diastolic) are collected after visits to the physician. The data inputs are corrected and audited by nurse coordinators and the team every 2-4 weeks. 5) The summary is preset for future periodic reports. It was set to be searchable by period of time from one to several months to years and searchable by service providers, and by name, by group or by individual physician. A whole staff team meeting, including IT staff, reviews the process and reports back every 2-3 months. Results Since June 2012, when the Hypertension Registry was created, the number of registrants has gradually increased through a better understanding of the team members (Figure 1). A total of 647 cases were registered during the first 7 months. 2 The Bangkok Medical Journal Vol. 5; February 2013

Hypertension Registry at the Bangkok Hospital Medical Center: The First 7 Months Experience Sex About 57 of cases were female. The outnumbering of men by women was also true for the total of hypertension cases at the Bangkok Hospital Medical Center as well as the cases of one physician (Figure 2). Age Most registrants (74.5) were aged between 51 and 80 years old compared to patients who registered in one physician s registry (Figure 3). Body Mass Index Of those, half of all patients had a BMI of more than 24.99 and were categorized as overweight (Figure 4). 700 600 500 400 300 200 100 0 12 Jun Hypertension Registry during the first 7 months Year 2012 29 149 225 413 568 647 Jul Aug Sep Oct Nov Dec History of risk factors According to an initial interview of 84 cases, 51.9 had dyslipidaemia and 34.8 had diabetes mellitus (DM). Heart disease was found in 4.4, kidney disease in 3.7, stroke in 3.2, and 0.7 of cases interviewed had peripheral vascular disorder as in Figure 5. Laboratory investigations: EKG was the most frequently ordered investigation (34.4) followed by chest x-ray, ABI, and MAU in 27.9, 19.5 and 18.1 respectively while ABI was the second most frequent investigation required in one physician s registry group (Figure 6). Antihypertensive medication: 3.9 of all registry cases did not need any antihypertensive agents to control blood pressure. Most cases (53.5) took only one item of antihypertensive medication. Of the remaining 32, 8.5, and 2.2 used 2, 3, and 4 antihypertensive medications respectively (Figure 7). ARB was the most common group prescribed for the treatment of hypertension (35.6). The second most common drug was DHP CCB (32.7) and if combined with non DHP CCB (2.9) then the percentage of the use of CCB would be equal to the ARB group. Beta blockers were used in 14.5 of cases and were more common than Diuretics (9.9), ACEI (3.0), alpha blockers (1.0) and DRI (0.3). Among 647 cases from the Hypertension Registry, there were no patients who used any antihypertensive medication marked as others (Figure 8). Achievement of blood pressure goal: approximately 90 of registrants had well controlled blood pressure by achieving SBP < 140 and DBP < 90 mmhg (Figure 9). Figure 1: Demonstrates the progression of the number of enrolled cases in the Hypertension Registry during the fi rst 7 months Female 52 Female 57 Female 60 Male 48 Male 43 Male 40 Overall 6,334 OPD patients with hypertension A total of 647 patients registered to the Hypertension Registry 244 patients registered to One physician Hypertension Registry Male Female Figure 2: Sex distribution of 6,334 hypertension patients from the whole medical center (the left is compared with 647 cases from The Hypertension Registry (middle) and 244 cases from one physician hypertension registry (right) during the same period. The Bangkok Medical Journal Vol. 5; February 2013 3

Rungtanapirom S, et al. 28 24 22.72 26.58 25.19 16 12 8 9.74 12.21 4 0 0.46 21-30 3.09 31-40 41-50 51-60 61-70 71-80 >= 80 Age range (years) 32 28 24 16 12 8 4 0 27.46 25.41 21.72 11.48 12.7 0.41 0.82 21-30 31-40 41-50 51-60 61-70 71-80 >= 80 Age range (years) Figure 3: Age distribution amongst 647 patients who participated in the Hypertension Registry compared to 244 patients from one physician s registry. 40 35 37.1 36.5 30 25 15 10 5 0 10 BMI < 20 BMI 20-24.99 BMI 25-29.99 BMI 16.4 BMI 30 45 40 35 41.8 34.4 30 25 15 10 10.7 13.1 5 0 BMI < 20 BMI 20-24.99 BMI 25-29.99 BMI BMI 30 Figure 4: The Body Mass Index (BMI) distribution of 647 registrants who participated in the Hypertension Registry compared to 244 cases from one physician s registry. 4 The Bangkok Medical Journal Vol. 5; February 2013

Hypertension Registry at the Bangkok Hospital Medical Center: The First 7 Months Experience 60 50 51.9 40 34.8 30 10 0 3.2 4.4 3.7 0.7 1.3 Stroke disease Heart disease Kidney disease Dyslipidemia DM PAD Smoking 60 50 48.9 40 35.1 30 10 0 5.4 3.7 4.5 1.1 1.1 Stroke disease Heart disease Kidney disease Dyslipidemia DM PAD Smoking Figure 5: Associated risk conditions from the history of 84 patients from the Hypertension Registry interviewed compared to 44 patients from one physician s registry. 40 35 34.4 30 27.9 25 15 10 5 0 19.5 EKG ABI CXR Investigations 18.1 Microalbumin 32 28 24 30.3 25.7 24.1 16 12 8 13.1 4 0 EKG ABI CXR Investigations Microalbumin Figure 6: Percentage of investigations done in 647 cases from the Hypertension Registry compared to 244 cases from one physician s registry. The Bangkok Medical Journal Vol. 5; February 2013 5

Rungtanapirom S, et al. 60 50 53.5 40 30 32 10 0 3.9 8.5 0 1 2 3 4 Heart Number of Antihypertensive Medicine 2.2 70 60 50 40 30 10 0 4.1 59.8 28.7 4.9 0 1 2 3 4 Heart Number of Antihypertensive Medicine 2.5 Figure 7: Distribution of registrants using 0 to 4 items of antihypertensive medications amongst 647 cases from the Hypertension Registry and 244 cases from one physician s registry. 40 35 30 25 32.7 35.6 15 10 14.5 9.9 5 0 2.9 3 1 0.3 DHP CCB ARB BetaBlocker Diuretics non DHP CCB ACEI AlphaBlocker DRI Group of Antihypertensive Medicine 40 35 30 25 32.8 36.6 15 10 5 0 16 5.6 4.5 3.8 0 0.7 DHP CCB ARB BetaBlocker Diuretics non DHP CCB ACEI AlphaBlocker DRI Group of Antihypertensive Medicine Figure 8: Group of antihypertensive medications amongst 647 cases from the Hypertension Registry compared to 244 cases from one physician s registry. 6 The Bangkok Medical Journal Vol. 5; February 2013

Hypertension Registry at the Bangkok Hospital Medical Center: The First 7 Months Experience 100 80 87.5 60 40 12.5 0 SBP < 140 and DBP < 90 SBP > 140 and DBP > 90 Blood Pressure Goal Achlevement 100 80 95.8 60 40 0 4.2 SBP < 140 and DBP < 90 SBP > 140 and DBP > 90 Blood Pressure Goal Achlevement Figure 9: Percentage of cases achieving goal of treatment, SBP < 140 and DBP < 90 in 337 cases from the Hypertension Registry and 120 cases from one physician s registry. Discussion During the initial 7 months of the Hypertension Registry, we can see many broad ideas that can be used to improve hypertension clinical services. About half of all cases were overweight (BMI > 24.99 kg/m 2 ), and an EKG was taken assess any left ventricular hypertrophy evidence (only about a third of participants), urine microalbumin was tested in less than a fifth of the cases despite much evidence to suggest that this simple test can warn us of the cardiovascular risk in hypertensive patients etc. All this information is critical for hospital staff to be able to plan for better services. Furthermore, the registry data can also be a good tool for patient education. It was surprising to discover that more than half of all patients only need one antihypertensive medication and about 90 of cases achieved the BP goal. These initial registry cases, however, will slowly and continuously accumulate, so it may be too soon to extrapolate, as this sample may not represent the reality. Time is needed for the registry system to develop and for staff to improve their skills and increase their experience. Also, larger numbers are required in the registry to help build a better picture of the current situation. This Hypertension Registry is a dynamic tool, able to accommodate frequent updates and to be adapted in the future if required. We hope to learn more from our information with a larger number of participants in the hypertension registry numbers, accompanied by a growth in global medical knowledge and guidelines. Conclusion The Hypertension Registry provides multiple benefits and valuable information. It is progressing well, and may yield firmer conclusions when the registry grows in numbers. Acknowledgements The authors and the Hypertensive Registry team would like to thank the CEO, the Bangkok Hospital Directors, the Medicine Patient Care Group Manager, and the President of the Medical Staff Organization of The Bangkok Hospital Medical Center for all their support towards this project s development. The Bangkok Medical Journal Vol. 5; February 2013 7

Rungtanapirom S, et al. References 1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. 2. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25:1751-62. 3. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-92. 4. Thai Hypertension Society Writing Group. Thai Guidelines on the treatment of hypertension update 2012. (Accessed January 2013, at http://www.thaihypertension.org/files/ 216_1.Hypertension_Guideline_2012.pdf.) 5. Yingchoncharoen T, Limpijankit T, Jongjirasiri S, et al. Arterial stiffness contributes to coronary artery disease risk prediction beyond the traditional risk score (RAMA-EGAT score). Heart Asia 2012;4:177-82 doi: 10.1136/heartasia-2011-010079. 6. Yambe T, Yoshizawa M, Saijo Y, et al. Brachio-ankle pulse wave velocity and cardio-ankle vascular index (CAVI). Biomed Pharmacother 2004;58:S95-8. 7. Arterial Stiffness Index CAVI ; CAVI (Cardio-Ankle Vascular Index). (Accessed January 2013, at http://www. fukuda.co.jp/english/products/special_features/vasera/ cavi.html) 8. Gojaseni P, Phaopha A, Chailimpamontree W, et al. Prevalence and risk factors of microalbuminuria in Thai nondiabetic hypertensive patients. Vasc Health Risk Manag 2010;6:157-65. 8 The Bangkok Medical Journal Vol. 5; February 2013